AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention

PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally …
( read original story …)


Advertisement